OT mobile menu

Search form



Are Some Cancer Drugs Costing Too Much for Too Little?

The cost of progression-free survival. Image © ALIENFORCE/Shutterstock.com 

Recent Content

A 43-year-old man presents with a mass at the level of the filum terminale. After a biopsy is performed, what is your diagnosis?

In my practice, I am constantly being asked how to properly treat scalp involvement in relation to these skin toxicities.

One of the confounding issues with treating patients with immunotherapy for hematologic diseases is the risk of relapse that can occur during and after treatment.

There is a lot of interest in a new treatment that kills approximately 90% of melanoma cancer cells, an astounding accomplishment for Richard Neubig, MD, PhD, who serves as chairperson of pharmacology toxicology at Michigan State University.

A new German multicenter study is suggesting that lutetium-177 (Lu-177)-labeled PSMA-617 may be a promising new therapeutic agent for radioligand therapy in men with metastatic castration-resistant prostate cancer.

A new study is suggesting it may be possible to shut down the circuits that drive the high tumorigenicity of prostate cancer cells leading to castration-resistant prostate cancer.

A study recently published is suggesting that a key drug target, CDK4/6, regulates a cancer metastasis protein, and may play a role in combating metastasis in triple-negative breast cancer. In addition, this new finding may point to a new way of preventing metastasis in other cancers.

By clicking Accept, you agree to become a member of the UBM Medica Community.